Ergosterol utilizes PDE4B and PDE4D, and adenosine targets PARP1, PTGDR2, PDE4A, PDE4B, PDE4C, PDE4D, and HMOX1 as co‐targeted proteins in the therapeutic approach for COPD. Here, PDE4D is linked to chronic obstructive pulmonary disease.